Clinical Trial Update: Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating 5-day dosing of ON 01910.Na in patients with myelodysplastic syndromes across risk categories, which has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• ON-01910.Na (ON-01910 sodium)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: WITHDRAWN